The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).
Armando Santoro
Consultant or Advisory Role - ArQule
Honoraria - Daiichi Sankyo
Research Funding - ArQule; Daiichi Sankyo
Camillo Porta
Consultant or Advisory Role - ArQule (U); Daiichi Sankyo (U)
Research Funding - ArQule; Daiichi Sankyo
Lorenza Rimassa
Research Funding - ArQule; Daiichi Sankyo
Ivan Borbath
Consultant or Advisory Role - ArQule (U); Daiichi Sankyo (U)
Research Funding - ArQule; Daiichi Sankyo
Bruno Daniele
Consultant or Advisory Role - ArQule (U); Bayer; Daiichi Sankyo
Honoraria - Bayer; Novartis
Research Funding - ArQule; Daiichi Sankyo
Richard S. Finn
Consultant or Advisory Role - ArQule (U); Daiichi Sankyo (U)
Jean-Luc Raoul
Consultant or Advisory Role - ArQule (U); Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo (U); Generex Biotechnology; Nordion
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb
Lawrence H. Schwartz
Consultant or Advisory Role - ArQule; Daiichi Sankyo (U)
Aiwu Ruth He
Consultant or Advisory Role - ArQule (U); Daiichi Sankyo (U)
Jorg Trojan
Consultant or Advisory Role - Daiichi Sankyo
Markus Peck-Radosavljevic
No relevant relationships to disclose
Giovanni Abbadessa
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Terri Robin Goldberg
Employment or Leadership Position - Daiichi Sankyo
Stock Ownership - Daiichi Sankyo
Jordi Bruix
Consultant or Advisory Role - Abbott Laboratories; ArQule; Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; ImClone Systems; Kowa ; Lilly; Novartis; Roche; Sanofi ; TERUMO; Wako
Research Funding - ArQule; Bayer; Daiichi Sankyo